Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.

Kelley R H Branch Gilles R Dagenais Álvaro Avezum Jan Basile Ignacio Conget Donlo William C CushmanPetr JanskyMark Lakshmanan Fernando Tomás Lanas Zanetti Lawrence Alan Leiter Prem Pais Nana Pogosova Peter Johann Raubenheimer Lars Ryden Jonathan Edward Shaw Wayne Huey Herng Sheu Theodora Temelkova-KurktschievM Angelyn BethelUlagamadesan VenkatesanRamasundarahettige ChinthanieJeffrey L Probstfield

Published in: European journal of heart failure (2022)

Dulaglutide was not associated with a reduction in HF events in patients with type 2 diabetes regardless of baseline HF status over 5.4 years of follow-up.

Keyphrases

heart failure
acute heart failure
left ventricular
cardiac resynchronization therapy
atrial fibrillation
type diabetes
glycemic control